Anti-tau aggregation therapies represent a promising disease-modifying approach for Alzheimer's disease and other tauopathies, including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These therapeutic strategies aim to prevent or reduce the formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated [tau protein](/proteins/tau). The key innovation in modern tau-targeted therapy is the integration of biomarker monitoring to guide treatment decisions, enabling personalized dosing and outcome assessment. [@j2023]
Mechanism of Action
Tau Aggregation Inhibition
The formation of tau aggregates involves the misfolding and polymerization of hyperphosphorylated tau protein into paired helical filaments (PHFs) and straight filaments (SFs). Anti-tau aggregation therapies work through several mechanisms: [@m2022]
Small molecule aggregation inhibitors: Compounds that bind to tau monomers and prevent their aggregation into oligomers and fibrils
Microtubule stabilizers: Agents that maintain tau's normal function in stabilizing microtubules, reducing the pool of free tau available for aggregation
Tau-directed antibodies: Immunotherapies that target extracellular tau species and facilitate their clearance
Biomarker Response Targets
Therapeutic efficacy is monitored through specific biomarker readouts: [@a2022]
[p-tau217](/biomarkers/p-tau-217): Expected 30-50% reduction from baseline with effective treatment
[p-tau181](/biomarkers/p-tau-181): Parallel reduction reflecting decreased tau pathology burden
Total tau (t-tau): CSF t-tau may decrease as neuronal tau release is reduced
Tau PET imaging: Reduced uptake kinetics indicating decreased tau accumulation
Clinical Development Landscape
Active Clinical Trials
Several anti-tau aggregation agents are in various stages of clinical development: [@r2022]
Biomarker-Guided Trial Designs
Modern trials incorporate biomarker enrichment strategies:
Tau PET-positive enrichment: Selecting patients with elevated tau PET signal for higher likelihood of responding
p-tau biomarker stratification: Using baseline p-tau levels to identify patients most likely to benefit
Bayesian adaptive designs: Allowing dose adjustment based on biomarker response
Therapeutic Approaches
1. Small Molecule Tau Aggregation Inhibitors
These oral agents target the nucleation and propagation of tau aggregates:
Mechanism: Bind to tau's microtubule-binding repeat domains, preventing β-sheet formation
[J. L. Moloney et al., "Tau-targeted immunotherapy: A review of anti-tau antibody trials in Alzheimer's disease," Alzheimer's & Dementia, vol. 19, no. 7, pp. 3124-3140, 2023 (2023)](https://doi.org/10.1002/alz.12935)
[M. J. Pontecorvo et al., "Tau PET imaging: A review of current status and future directions," Journal of Nuclear Medicine, vol. 63, no. 11, pp. 1623-1630, 2022 (2022)](https://doi.org/10.2967/jnumed.122.308288)
[A. C. van der Kant et al., "Tau aggregation inhibitors as disease-modifying therapy for Alzheimer's disease," Nature Reviews Drug Discovery, vol. 21, pp. 209-222, 2022 (2022)](https://doi.org/10.1038/s41573-021-00303-9)
[R. J. Bateman et al., "The anti-tau antibody semorinemab in mild-to-moderate Alzheimer's disease," Alzheimer's & Dementia, vol. 18, no. S6, pp. e062234, 2022 (2022)](https://doi.org/10.1002/alz.062234)
[S. Janelidze et al., "Plasma P-tau217 predicts response to anti-amyloid and anti-tau immunotherapy," Nature Medicine, vol. 29, pp. 1954-1963, 2023 (1954)](https://doi.org/10.1038/s41591-023-02326-3)
[G. M. Shankar et al., "Tau biology and targeted therapies: A comprehensive review," Brain, vol. 146, no. 4, pp. 1345-1365, 2023 (2023)](https://doi.org/10.1093/brain/awac388)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate